Cambridge Healthtech Institute’s 2nd Annual

Antibody Forum – Part 2

Engineering and Development

September 18-19, 2019


Discovery on Target’s new Antibody Forum offers research scientists working at the R&D stage the opportunity to participate in a novel meeting format that will encourage discussion and the exchange of information on the application of new science and technology for the discovery of new biotherapeutics.  The meeting will feature short presentations, panel discussions and an “in the round” audience format that allows a sharing of ideas and experiences.


Who should attend: Industry Discovery, Engineering and Development Scientists working to discover and advance novel biotherapeutics for cancer and other indications.


Coverage will include, but is not limited to:


Transitioning from Discovery into Development

  • Assays/workflows to evaluate biology, drug-like properties and developability at high throughput
  • The pros and cons of a strategy of “engineering out” liabilities
  • Best practices for the design and application of screening funnels
  • Decision making when using in vitro libraries
  • Solutions to major challenge areas (prediction of PK, post-translational modifications, glycans)

Development Challenges of New Modalities

  • Evaluation and planning for entirely new modalities
  • CNS targets and crossing the BBB barrie
  • Emerging modalities: exosomes, nanoparticles, liposomal formulations
  • Modalities on the horizon; the future of biotherapeutics
  • Developing an R&D capability for cell and gene therapies

Development of Complex Biologics

  • Bispecific/multispecific antibodies and format selection for specific applications
  • Novel conjugations and the future course of ADCs
  • Understanding the function effects of a naked antibody before conjugation
  • Agonist antibodies
  • Targeting large protein complexes

Overcoming the Barriers to Development or Clinical Stage Advancement

  • Lessons learned from failed antibody programs
  • Engineering issues; low/high affinity, cross-reactivity, degree of agonism, humanization
  • Glycosylation of antibodies
  • Aggregation and poor stability


If you would like to submit a proposal to give a presentation at this meeting, please click here.


The deadline for priority consideration is February 27, 2019.


All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


For more details on the conference, please contact:
Kent Simmons

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 207-869-9199


For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286

Premier Sponsors

Ablexis Alivamab_stacked



OmniAb Ligand_Pharmaceuticals